Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.361 USD | 0.00% | -5.99% | -81.49% |
May. 15 | Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
Financials (USD)
Sales 2022 | 10.88 | Sales 2023 | 19.59 | Capitalization | 4.9M |
---|---|---|---|---|---|
Net income 2022 | -25M | Net income 2023 | -14M | EV / Sales 2022 | 568,219 x |
Net cash position 2022 | 3.04M | Net cash position 2023 | 385K | EV / Sales 2023 | 230,324 x |
P/E ratio 2022 |
-0.19
x | P/E ratio 2023 |
-0.29
x | Employees | 19 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.75% |
Latest transcript on Agile Therapeutics, Inc.
1 day | -0.82% | ||
1 week | -3.71% | ||
1 month | -10.82% | ||
3 months | -57.53% | ||
6 months | -83.29% | ||
Current year | -81.49% |
Managers | Title | Age | Since |
---|---|---|---|
Al Altomari
CEO | Chief Executive Officer | 65 | 04-01-31 |
Scott Coiante
DFI | Director of Finance/CFO | 57 | 10-11-30 |
Paul Korner
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-08-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Al Altomari
CEO | Chief Executive Officer | 65 | 04-01-31 |
Seth Fischer
BRD | Director/Board Member | 68 | 16-07-27 |
John Hubbard
BRD | Director/Board Member | 67 | 14-11-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 0.361 | 0.00% | 3 909 |
24-05-31 | 0.361 | -0.82% | 46,788 |
24-05-30 | 0.364 | 0.00% | 46,460 |
24-05-29 | 0.364 | -5.21% | 31,567 |
24-05-28 | 0.384 | +2.43% | 5,918 |
Delayed Quote OTC Markets, May 31, 2024 at 03:55 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-81.49% | 2.48M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.03% | 21.96B | |
-8.24% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- AGRX Stock